96 related articles for article (PubMed ID: 36866550)
1. To Investigate the Occurrence and Development of Colorectal Cancer Based on the PI3K/AKT/mTOR Signaling Pathway.
Zhong J; Ding S; Zhang X; Di W; Wang X; Zhang H; Chen Y; Zhang Y; Hu Y
Front Biosci (Landmark Ed); 2023 Feb; 28(2):37. PubMed ID: 36866550
[TBL] [Abstract][Full Text] [Related]
2. PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment.
Leiphrakpam PD; Are C
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542151
[TBL] [Abstract][Full Text] [Related]
3. B7-H4 facilitates proliferation and metastasis of colorectal carcinoma cell through PI3K/Akt/mTOR signaling pathway.
Li C; Zhan Y; Ma X; Fang H; Gai X
Clin Exp Med; 2020 Feb; 20(1):79-86. PubMed ID: 31664539
[TBL] [Abstract][Full Text] [Related]
4. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
Glaviano A; Foo ASC; Lam HY; Yap KCH; Jacot W; Jones RH; Eng H; Nair MG; Makvandi P; Geoerger B; Kulke MH; Baird RD; Prabhu JS; Carbone D; Pecoraro C; Teh DBL; Sethi G; Cavalieri V; Lin KH; Javidi-Sharifi NR; Toska E; Davids MS; Brown JR; Diana P; Stebbing J; Fruman DA; Kumar AP
Mol Cancer; 2023 Aug; 22(1):138. PubMed ID: 37596643
[TBL] [Abstract][Full Text] [Related]
5. PI3K/AKT Signaling Pathway Mediated Autophagy in Oral Carcinoma - A Comprehensive Review.
Rajendran P; Sekar R; Dhayasankar PS; Ali EM; Abdelsalam SA; Balaraman S; Chellappan BV; Metwally AM; Abdallah BM
Int J Med Sci; 2024; 21(6):1165-1175. PubMed ID: 38774756
[TBL] [Abstract][Full Text] [Related]
6. RFC2 promotes aerobic glycolysis and progression of colorectal cancer.
Lou F; Zhang M
BMC Gastroenterol; 2023 Oct; 23(1):353. PubMed ID: 37821801
[TBL] [Abstract][Full Text] [Related]
7. Pyrvinium Pamoate Induces Cell Apoptosis and Autophagy in Colorectal Cancer.
Zheng W; Chen K; Lv Y; Lao W; Zhu H
Anticancer Res; 2024 Mar; 44(3):1193-1199. PubMed ID: 38423653
[TBL] [Abstract][Full Text] [Related]
8. 5-methoxytryptophan induced apoptosis and PI3K/Akt/FoxO3a phosphorylation in colorectal cancer.
Zhao TL; Qi Y; Wang YF; Wang Y; Liang H; Pu YB
World J Gastroenterol; 2023 Dec; 29(47):6148-6160. PubMed ID: 38186686
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia upregulating ACSS2 enhances lipid metabolism reprogramming through HMGCS1 mediated PI3K/AKT/mTOR pathway to promote the progression of pancreatic neuroendocrine neoplasms.
Gu D; Ye M; Zhu G; Bai J; Chen J; Yan L; Yu P; Lu F; Hu C; Zhong Y; Liu P; He Q; Tang Q
J Transl Med; 2024 Jan; 22(1):93. PubMed ID: 38263056
[TBL] [Abstract][Full Text] [Related]
10. [Effect of high selenium on insulin signaling pathway PI3K-AKT-mTOR in L02 cells].
Wang Q; Zhang X; Wang J; Liu Y; Han F; Xiang X; Guo Y; Huang Z
Wei Sheng Yan Jiu; 2024 Jan; 53(1):77-87. PubMed ID: 38443176
[TBL] [Abstract][Full Text] [Related]
11. SULF1 regulates malignant progression of colorectal cancer by modulating ARSH via FAK/PI3K/AKT/mTOR signaling.
Zhu W; Wu C; Liu Z; Zhao S; Cheng X; Huang J
Cancer Cell Int; 2024 Jun; 24(1):201. PubMed ID: 38844922
[TBL] [Abstract][Full Text] [Related]
12. Roles of Rictor alterations in gastrointestinal tumors (Review).
Cao R; Guo S; Min L; Li P
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38186315
[TBL] [Abstract][Full Text] [Related]
13. PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies-New Therapeutic Possibilities.
Wiese W; Barczuk J; Racinska O; Siwecka N; Rozpedek-Kaminska W; Slupianek A; Sierpinski R; Majsterek I
Cancers (Basel); 2023 Nov; 15(21):. PubMed ID: 37958470
[TBL] [Abstract][Full Text] [Related]
14. Role of m6A modification in regulating the PI3K/AKT signaling pathway in cancer.
Liu J; Gu X; Guan Z; Huang D; Xing H; Zheng L
J Transl Med; 2023 Nov; 21(1):774. PubMed ID: 37915034
[TBL] [Abstract][Full Text] [Related]
15. Leukotriene B4 receptor knockdown affects PI3K/AKT/mTOR signaling and apoptotic responses in colorectal cancer.
Tang C; Wang A; Zhao Y; Mou W; Jiang J; Kuang J; Sun B; Tang E
Biomol Biomed; 2024 Jan; ():. PubMed ID: 38259082
[TBL] [Abstract][Full Text] [Related]
16. SERPINH1 promoted the proliferation and metastasis of colorectal cancer by activating PI3K/Akt/mTOR signaling pathway.
Jin XS; Chen LX; Ji TT; Li RZ
World J Gastrointest Oncol; 2024 May; 16(5):1890-1907. PubMed ID: 38764814
[TBL] [Abstract][Full Text] [Related]
17. Development and Clinical Applications of PI3K/AKT/mTOR Pathway Inhibitors as a Therapeutic Option for Leukemias.
DA Costa Machado AK; Machado CB; DE Pinho Pessoa FMC; Barreto IV; Gadelha RB; DE Sousa Oliveira D; Ribeiro RM; Lopes GS; DE Moraesfilho MO; DE Moraes MEA; Khayat AS; Moreira-Nunes CA
Cancer Diagn Progn; 2024; 4(1):9-24. PubMed ID: 38173664
[TBL] [Abstract][Full Text] [Related]
18. PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Peng Y; Wang Y; Zhou C; Mei W; Zeng C
Front Oncol; 2022; 12():819128. PubMed ID: 35402264
[TBL] [Abstract][Full Text] [Related]
19. Urolithin C suppresses colorectal cancer progression via the AKT/mTOR pathway.
Yang H; Wu B; Yang Q; Tan T; Shang D; Chen J; Cao C; Xu C
J Nat Med; 2024 Jun; ():. PubMed ID: 38849679
[TBL] [Abstract][Full Text] [Related]
20. Retracted Article: Daphnetin inhibits proliferation and glycolysis in colorectal cancer cells by regulating the PI3K/Akt signaling pathway.
He Z; Dong W; Yao K; Qin C; Duan B
RSC Adv; 2018 Oct; 8(60):34483-34490. PubMed ID: 35548643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
